生长刺激表达基因2蛋白、脑钠肽检测对心力衰竭诊断的临床效果成效

许可 贾慧婕^{（通讯作者）}

河南医药大学基础医学院，河南新乡，453000；

摘要：目的：分析可溶性生长刺激表达基因2蛋白（sST2）及脑钠肽相关指标的心衰诊断价值与试剂评价意义。方法：基于公开指南、临床研究与监管资料进行叙述性分析，区分B型利钠肽（BNP）与N末端B型利钠肽原（NT-proBNP），不重新合并统计量。结果：sST2诊断Meta分析的合并敏感度为0.72、特异度0.65、AUC为0.75；420例住院患者中，sST2、NT-proBNP及联合模型AUC分别为0.797、0.813和0.857。肾功能、感染及平台偏倚影响结果解释。结论：BNP/NT-proBNP是心衰诊断的重要指标，sST2具有补充诊断与风险分层潜力；联合检测的增量价值须在目标人群及具体平台验证。

关键词：可溶性生长刺激表达基因2蛋白；脑钠肽；NT-proBNP；心力衰竭；辅助诊断

参考文献

[1]中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52(3):235-275.

[2]YANG C, FAN Z, WU J, et al. The diagnostic value of soluble ST2 in heart failure: a meta-analysis[J]. Frontiers in Cardiovascular Medicine, 2021, 8: 685904.

[3]MA H, ZHOU J, ZHANG M, et al. The diagnostic accuracy of N-terminal pro-B-type natriuretic peptide and soluble ST2 for heart failure in chronic kidney disease patients: a comparative analysis[J]. Medical Science Monitor, 2023, 29: e940641.

[4]CHEN Y, GUAN J, QI C, et al. Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure[J]. ESC Heart Failure, 2024, 11(5): 2857-2868.

[5]U.S. Food and Drug Administration. Presage ST2 Assay: substantial equivalence determination decision summary, K111452[EB/OL]. (2011-12-09)[2026-09-22]. https://www.accessdata.fda.gov/cdrh_docs/reviews/K111452.pdf.

[6]DAVINI F, FOGOLARI M, D’AVANZO G, et al. Soluble suppression of tumorigenicity 2 (sST2) as a diagnostic and prognostic marker in acute heart failure and sepsis: a comparative analysis[J]. Diagnostics, 2025, 15(8): 1010.

[7]GAO S, LI J. Development of a novel homogeneous nanoparticle-based assay for rapid and high-throughput quantitation of the sST2 protein in human serum[J]. International Journal of Nanomedicine, 2020, 15: 10539-10546.

[8]KIM H, LEE T H, HUR M, et al. Performance evaluation of AFIAS ST2 and ichroma ST2 assays in comparison with Presage ST2 assay[J]. Reviews in Cardiovascular Medicine, 2023, 24(4): 100.